Detalhe da pesquisa
1.
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Hepatology
; 77(3): 729-744, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302667
2.
Targeting Mitosis in Cancer: Emerging Strategies.
Mol Cell
; 60(4): 524-36, 2015 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590712
3.
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Proc Natl Acad Sci U S A
; 114(12): 3127-3132, 2017 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270606
4.
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Br J Cancer
; 121(4): 318-324, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31303643
5.
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Invest New Drugs
; 34(5): 614-24, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27406088
6.
Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Bioorg Med Chem Lett
; 26(15): 3562-6, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27335255
7.
2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation.
Proc Natl Acad Sci U S A
; 109(51): 21034-9, 2012 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-23213242
8.
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Leukemia
; 38(3): 502-512, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114624
9.
DJ-1, a novel regulator of the tumor suppressor PTEN.
Cancer Cell
; 7(3): 263-73, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15766664
10.
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations.
Sci Adv
; 8(36): eabq4293, 2022 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36070391
11.
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Br J Haematol
; 150(3): 313-25, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20560971
12.
Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Nat Commun
; 10(1): 2678, 2019 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31213601
13.
Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Nat Commun
; 10(1): 4069, 2019 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31481706
14.
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
Cancer Res
; 63(1): 196-206, 2003 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12517798
15.
Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.
Cancer Res
; 64(9): 3271-5, 2004 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15126369
16.
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.
ACS Med Chem Lett
; 7(7): 671-5, 2016 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27437075
17.
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
J Med Chem
; 58(8): 3366-92, 2015 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25763473
18.
A Density Functional Study of Active Site Models for Xanthine Oxidase.
Inorg Chem
; 35(19): 5720-5724, 1996 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-11666767
19.
Fusion of the CH1 domain of IgG1 to epidermal growth factor (EGF) prolongs its retention in the blood but does not increase tumor uptake.
Cancer Biother Radiopharm
; 17(6): 665-71, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12537670
20.
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
Cancer Cell
; 26(2): 163-76, 2014 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25043604